Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet ...
In this analysis, researchers aimed to determine whether intermediate dose escalation is beneficial in resectable, stage III NSCLC patients who receive definitive concurrent chemoradiation followed by ...
The IMMUNEBOOST-HPV trial investigated whether adding nivolumab (Opdivo) immunotherapy before standard chemoradiation could improve outcomes for patients with high-risk oropharyngeal cancer. Although ...
In this study, researchers reported on 10-year follow-up of a phase 3 trial comparing surgery to chemoradiation boost in resectable, advanced NSCLC.
"The FDA approval of Optune Pax marks the first new treatment in decades for people living with locally advanced pancreatic ...
Concurrent chemoradiotherapy administered either before surgery or as definitive treatment has a central role in the multimodality treatment of locally advanced esophageal cancer. Initial studies of ...
This article reviews the current literature pertaining to neoadjuvant chemotherapy, concurrent chemoradiation (CRT), and adjuvant chemotherapy for high-risk ESTS. Although the data are limited, there ...
City of Hope® Research Spotlight offers a glimpse into groundbreaking scientific and clinical discoveries advancing lifesaving cures for ...
City of Hope Research Spotlight offers a glimpse into groundbreaking scientific and clinical discoveries advancing lifesaving cures for patients with cancer, diabetes and other chronic, ...
Patients with vs without rheumatoid arthritis have higher long-term all-cause and cardiovascular mortality after acute myocardial infarction, despite receiving comparable inpatient care. Individuals ...
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced finalization of a protocol amendment to the ongoing ...
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results